In silico modeling has transformed the design of pharmaceutical inhalation compounds into a potent platform to simulate and optimize the delivery systems in drug design for inhalation therapy. These computational methods provide accurate predictions of drug behavior within the respiratory tract from particle deposition patterns to aerosol dynamics and pharmacokinetic-pharmacodynamic (PK-PD) profiles. This approach accelerates drug development by reducing reliance on extensive experimental trials, optimizing formulation and device efficiency, and ultimately enhancing the targeted delivery of therapies for respiratory infections and conditions. This chapter explores the major of inhalation therapy which includes optimization of particles size, innovation of various aerosolization techniques, and advancements in inhalation devices such as dry powder inhalers, and smart inhalers. It also focuses on the importance of computational fluid dynamics in modeling, aerosol behavior and its provision for an inclusion of patient-specific factors in drug deposition. It covers multifaceted challenges related to formulation stability, regulatory compliance, and device design which interleave between drug properties, mechanisms of delivery, and adherence to treatment. It goes further to discuss emerging trends in the use of artificial intelligence (AI), machine learning (ML), and hybrid in silico models to improve the accuracy of predictions and to individualize treatment approaches. The potential of in silico modeling to overcome classic hurdles of drug development to induce innovation, and ultimately facilitate the development of more effective, patient-centered inhalation therapies is important. This approach promises to redefine the scientific pharmaceutical landscape in terms of respiratory health through precision engineering and cutting-edge technology.